Daily Morning Note – 3 September 2021

Dear valued client,

Major US equity indices again finished at records on Thursday following better weekly jobless claim data ahead of the closely-watched August employment report.

The Labour Department reported a seasonally adjusted 340,000 new filings for aid in the week ended August 28, 14,000 less than the previous week’s upwardly revised level and the lowest since Covid-19 caused millions of layoffs in March 2020.

The report comes ahead of Friday’s labour data, which is expected to show the United States added 750,000 positions last month, with the unemployment rate falling to 5.2 per cent.

The Dow Jones Industrial Average ended up 0.4 per cent at 35,443.82.

The broad-based S&P 500 gained 0.3 per cent to 4,536.95, while the tech-rich Nasdaq Composite Index advanced 0.1 per cent to 15,331.18.


BREAKING NEWS

SG News

Singtel on Thursday announced that its joint-venture company, PT Telekomunikasi Selular (Telkomsel) has entered into a sale-and-purchase agreement for the sale of 4,000 telecommunication towers to PT Dayamitra Telekomunikasi (Mitratel) for IDR6.2 trillion (S$580 million). Mitratel is a subsidiary of PT Telkom Indonesia Tbk, which provides telecommunications infrastructure and has managed over 24,000 telecommunication towers across Indonesia. As part of the transaction, Telkomsel, in which Singtel has a 35 per cent interest in, has also entered into a 10-year lease arrangement with Mitratel for rental of tower space, which will take effect from the transfer of the towers to Mitratel. The transaction will enable Telkomsel to optimise its capital structure as it focuses on its core business of providing digital connectivity services to customers in Indonesia, said Singtel in a bourse filing.

Eleven of Singapore’s smaller Reits have made it into the FTSE EPRA Nareit Global Real Estate Index series, according to the index series’ quarterly review changes announced by FTSE Russell on Sept 1. Prior to the review, there were 17 Singapore Reits and property trusts in the FTSE EPRA Nareit Developed Index, according to the index’s factsheet as at July 30, 2021. The entries into the FTSE EPRA Nareit Global Developed Index include AIMS APAC Reit, ARA Logos Logistics Trust, Cromwell European Reit, ESR-Reit, Far East Hospitality Trust, Keppel Pacific Oak US Reit, Lendlease Global Commercial Reit, OUE Commercial Reit, Prime US Reit, SPH Reit and Starhill Global Reit.


There are no changes to the Straits Times Index (STI) constituents, following the September quarterly review. The STI reserve list, comprising the five highest-ranking non-constituents of the STI by market capitalisation, will be (in order of size) Olam International, Suntec Real Estate Investment Trust (Reit), Keppel Reit, Frasers Centrepoint Trust and NetLink NBN Trust. Stocks on the reserve list will replace any constituents that become ineligible as a result of corporate actions before the next review. The next quarterly review of the STI will take place in December. The STI, Singapore’s main stock market benchmark is jointly calculated by FTSE Russell, the index administrator; Singapore Press Holdings, which publishes The Business Times; and the Singapore Exchange (SGX).


US News

Apple further loosened App Store rules on Wednesday, allowing some content companies like Netflix to provide links to their websites so that customers can sign up for paid accounts. The concession was part of a settlement with Japan’s anti-trust regulator, which said the change was enough for it to close a five-year investigation into Apple that focused on video and music apps but did not consider games. The US tech giant, however, must still contend with a raft of other legal and regulatory challenges to rules that it forces game makers to follow, including a closely watched antitrust lawsuit brought by “Fortnite” creator Epic Games. The ban on providing separate links was lifted for so-called reader apps which provide content such as e-books, video and music that don’t offer a free tier of service, instead requiring payment at sign-up.

US medtech firm Baxter International said on Thursday it would buy rival Hill-Rom Holdings for about US$10.5 billion, adding smart hospital beds to its portfolio of patient monitoring and diagnostic products. Baxter said it would pay US$156 per Hill-Rom share, a premium of 7.5 per cent to the stock’s last close. Hill-Rom shares were trading up 3 per cent at US$149.85 before the bell on Thursday, while Baxter shares rose 1 per cent. Media reports had earlier said the companies had been in talks for months and Hill-Rom in July had rejected a US$144 per share offer from Baxter, deeming it too low. On Monday, Reuters reported the companies were nearing a deal. Medical equipment makers in recent months have broadened their offerings through acquisitions to cash in on the sector’s recovery from the pandemic-driven slump last year.

Oil prices rose more than US$1 a barrel on Thursday, rebounding on optimism about global economic growth despite the coronavirus pandemic, and after US crude inventories fell more than anticipated. Brent crude ended up US$1.44, or 2 per cent, at US$73.03 a barrel. West Texas Intermediate (WTI) crude settled up US$1.40, or 2 per cent, to US$69.99 a barrel. The rally briefly pushed US crude futures above the 50-day moving average for the first time in a month, a signal of bullishness for investors. In addition, later-dated crude contracts rallied more than the front-month, another sign that market participants expect demand to rise as supply declines.


Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, CNBC, PSR

RESEARCH REPORTS

Welcome to Phillip Securities Research’s second issue of our Ground View magazine.

In this month’s issue on Pre- and post-covid: Healthcare in Singapore we will cover:

1. Composition of Singapore healthcare service industry.

2. Flashback on the performance of Singapore’s healthcare stocks through two decades

3. How healthcare companies in Singapore performance defied the pandemic.

4. An interview with Q & M Dental group founder, Dr Ng Chin Siau.

5. Case study of iX Biopharma’s US FDA Phase 1 and Phase 2 trials.

>> Read more Research reports

HK Reports – Read up on our Hong Kong reports here

Webinar Of The Week

Weekly Market Outlook: Yoma, Koda ltd, BRC Asia, Netlink NBN Trust, Phillip on the ground, SG Weekly

Date: 30 Aug 2021

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #29 Keppel Corporation; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information





Disclaimer
The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.

 

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com